Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma

Cancer Immunology, Immunotherapy

Volumn 66, Issue 4, 2017, Pages 475-489

  Chen, Cheng ^a   Li, Kesang ^a   Jiang, Hua ^a   Song, Fei ^a   Gao, Huiping ^a   Pan, Xiaorong ^a   Shi, Bizhi ^a   Bi, Yanyu ^a   Wang, Huamao ^b   Wang, Hongyang ^a,c,d   Li, Zonghai ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CARsgen Therapeutics   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d National Scientific Centre for Liver Cancer   (China)

Author keywords

Asialoglycoprotein receptor 1; Chimeric antigen receptors; Dual targeted T cells; Glypican 3; Hepatocellular carcinoma

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; ASIALOGLYCOPROTEIN RECEPTOR 1; CD28 ANTIGEN; GAMMA INTERFERON; GLYPICAN 3; INTERLEUKIN 2; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL XL; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ASGR1 PROTEIN, HUMAN; CANCER VACCINE; CYTOKINE; GLYPICAN; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CANCER INHIBITION; CELL MATURATION; CELL PROLIFERATION; CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR XENOGRAFT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTIBODY SPECIFICITY; CARCINOMA, HEPATOCELLULAR; DRUG SCREENING; GENETICS; IMMUNOLOGY; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; PROCEDURES; SCID MOUSE; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ASIALOGLYCOPROTEIN RECEPTOR; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; GLYPICANS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; ORGAN SPECIFICITY; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85007471245     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1949-8     Document Type: Article

References (44)

1. Li ZH, Chen C, Li KS, Jiang H, Song F, Gao HP, Pan XR, Shi BZ, Bi YY, Wang HM, Wang HY (2016) Development of T-cells carrying two complementary chimeric antigen receptors against GPC3 and ASGR1 for the treatment of hepatocellular carcinoma. Mol Ther 24(supplement 1):S79. doi:10.1038/mt.2016.78
2. Cancer IAfRo (2014) World cancer report 2014. WHO, Geneva
3. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J, Barcelona Liver Cancer G (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734–1739. doi:10.1016/S0140-6736(02)08649-X
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Group SIS (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390. doi:10.1056/NEJMoa0708857
5. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12(20 Pt 1):6106–6115. doi:10.1158/1078-0432.CCR-06-1183
6. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MC (2007) Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 15(4):825–833. doi:10.1038/sj.mt.6300104
7. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, Pastan I, June CH (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 106(9):3360–3365. doi:10.1073/pnas.0813101106
8. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73. doi:10.1126/scitranslmed.3002842
9. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725–733. doi:10.1056/NEJMoa1103849
10. Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, Kong J, Wang H, Yang S, Gu J, Li Z (2014) Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 20(24):6418–6428. doi:10.1158/1078-0432.CCR-14-1170
11. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM (2008) Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 129(6):899–906. doi:10.1309/HCQWPWD50XHD2DW6
12. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843–851. doi:10.1038/mt.2010.24
13. Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, Burbridge SE, Box C, Eccles SA, Maher J (2012) Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 32(5):1059–1070. doi:10.1007/s10875-012-9689-9
14. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M (2013) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31(1):71–75. doi:10.1038/nbt.2459
15. Fiume L, Di Stefano G, Busi C, Mattioli A, Bonino F, Torrani-Cerenzia M, Verme G, Rapicetta M, Bertini M, Gervasi GB (1997) Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor. J Viral Hepat 4(6):363–370
16. Coulstock E, Sosabowski J, Ovecka M, Prince R, Goodall L, Mudd C, Sepp A, Davies M, Foster J, Burnet J, Dunlevy G, Walker A (2013) Liver-targeting of interferon-alpha with tissue-specific domain antibodies. PLoS ONE 8(2):e57263. doi:10.1371/journal.pone.0057263
17. Mu H, Lin KX, Zhao H, Xing S, Li C, Liu F, Lu HZ, Zhang Z, Sun YL, Yan XY, Cai JQ, Zhao XH (2014) Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry. World J Gastroenterol 20(19):5826–5838. doi:10.3748/wjg.v20.i19.5826
18. Witzigmann D, Quagliata L, Schenk SH, Quintavalle C, Terracciano LM, Huwyler J (2016) Variable asialoglycoprotein receptor 1 expression in liver disease: implications for therapeutic intervention. Hepatol Res 46(7):686–696. doi:10.1111/hepr.12599
19. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, Vignali DA (2004) Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat Biotechnol 22(5):589–594. doi:10.1038/nbt957
20. Wang H, Zhou M, Shi B, Zhang Q, Jiang H, Sun Y, Liu J, Zhou K, Yao M, Gu J, Yang S, Mao Y, Li Z (2011) Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia 13(5):461–471
21. Kuroda H, Kutner RH, Bazan NG, Reiser J (2009) Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. J Virol Methods 157(2):113–121. doi:10.1016/j.jviromet.2008.11.021
22. Li K, Pan X, Bi Y, Xu W, Chen C, Gao H, Shi B, Jiang H, Yang S, Jiang L, Li Z (2016) Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma. Oncotarget 7(3):2496–2507. doi:10.18632/oncotarget.6595
23. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1(11):1311–1318
24. Shi B, Abrams M, Sepp-Lorenzino L (2013) Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. J Histochem Cytochem 61(12):901–909. doi:10.1369/0022155413503662
25. Di Tommaso L, Destro A, Seok JY, Balladore E, Terracciano L, Sangiovanni A, Iavarone M, Colombo M, Jang JJ, Yu E, Jin SY, Morenghi E, Park YN, Roncalli M (2009) The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 50(4):746–754. doi:10.1016/j.jhep.2008.11.014
26. Li J, Gao JZ, Du JL, Wei LX (2014) Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 20(20):6336–6344. doi:10.3748/wjg.v20.i20.6336
27. Hass HG, Jobst J, Scheurlen M, Vogel U, Nehls O (2015) Gene expression analysis for evaluation of potential biomarkers in hepatocellular carcinoma. Anticancer Res 35(4):2021–2028
28. Trere D, Fiume L, De Giorgi LB, Di Stefano G, Migaldi M, Derenzini M (1999) The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells. Br J Cancer 81(3):404–408. doi:10.1038/sj.bjc.6690708
29. Shindo G, Endo T, Onda M, Goto S, Miyamoto Y, Kaneko T (2013) Is the CD4/CD8 ratio an effective indicator for clinical estimation of adoptive immunotherapy for cancer treatment? JCT 4(8):1382–1390. doi:10.4236/jct.2013.48164
30. Yang S, Gattinoni L, Liu F, Ji Y, Yu Z, Restifo NP, Rosenberg SA, Morgan RA (2011) In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunol Immunother 60(5):739–749. doi:10.1007/s00262-011-0977-7
31. Sallusto F, Geginat J, Lanzavecchia A (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22:745–763. doi:10.1146/annurev.immunol.22.012703.104702
32. Croft M (2003) Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev 14(3–4):265–273
33. Rudd CE, Schneider H (2003) Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol 3(7):544–556. doi:10.1038/nri1131
34. Watts TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23:23–68. doi:10.1146/annurev.immunol.23.021704.115839
35. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M, Heslop HE (2011) CARs on track in the clinic. Mol Ther 19(3):432–438. doi:10.1038/mt.2011.1
36. Stauss HJ, Morris EC (2013) Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther 20(11):1029–1032. doi:10.1038/gt.2013.34
37. Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, Powell DJ Jr (2013) Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res 1(1):43–53. doi:10.1158/2326-6066.CIR-13-0008
38. Takezawa R, Shinzawa K, Watanabe Y, Akaike T (1993) Determination of mouse major asialoglycoprotein receptor cDNA sequence. Biochim Biophys Acta 1172(1):220–222
39. Soukharev S, Berlin WK, Hanover JA, Bethke B, Sauer B (2000) Organization of the mouse ASGR1 gene encoding the major subunit of the hepatic asialoglycoprotein receptor. Gene 241(2):233–240
40. Nakano K, Yoshino T, Nezu J, Tsunoda H, Igawa T, Konishi H, Tanaka M, Sugo I, Kawai S, Ishiguro T, Kinoshita Y (2007) Anti-glypican 3 antibody. US 2007/0190599 A l [United States Patent Application Publication]
41. Weijtens ME, Hart EH, Bolhuis RL (2000) Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther 7(1):35–42. doi:10.1038/sj.gt.3301051
42. Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, Lee DA, Heimberger AB, Champlin RE, Cooper LJ (2015) Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res 75(17):3505–3518. doi:10.1158/0008-5472.CAN-15-0139
43. Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL (2015) 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21(6):581–590. doi:10.1038/nm.3838
44. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23(9):1126–1136. doi:10.1038/nbt1142